United States Patent RE44599: Scope, Claim Construction, and US Landscape for Hematopoietic-Cancer Methods
What does RE44599 cover in the US market?
US RE44599 is a reissue patent directed to method-of-use claims for inhibiting the growth or proliferation of hematopoietic-origin cancer cells and for treating hematologic malignancies by administering an identified small-molecule scaffold. The claims are written as treatment/inhibition methods, with downstream infringement tied to (i) the cancer type (hematopoietic), (ii) the administration of an “effective amount,” and (iii) identity/characterization of the compound, including S-enantiomer dependence in dependent claims.
Claim set (as provided)
- Claim 1: Method of inhibiting growth/proliferation of hematopoietic-origin cancer cells by contacting the cells with an effective amount of a compound (or pharmaceutically acceptable salt).
- Claim 2: Hematopoietic cancer is lymphoma, leukemia, or multiple myeloma cells.
- Claim 3: Compound is the S-enantiomer (or pharmaceutically acceptable salt).
- Claim 4: Treat lymphoma/leukemia/multiple myeloma in a subject by administering an effective amount of 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (or salt).
- Claim 5: Conditions include Burkitt’s lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, lymphocytic lymphoma, lymphocytic leukemia, multiple myeloma, chronic myeloid leukemia.
- Claim 6: Compound in claim 4 is the S-enantiomer (or salt).
How broad is the scope by claim?
Scope analysis turns on what each element requires.
Independent foothold: Claim 1 (method-of-inhibition; compound “any”)
Claim 1 is structurally broad:
- It covers “contacting cancer cells” with an “effective amount.”
- It limits the target cells to “hematopoietic origin.”
- It does not in the claim text (as provided) specify the compound identity; it only requires “a compound” or salt that would fall under the patent’s specification. The practical scope is therefore tied to the definition of “compound” in the specification and any claim-mapping that the reissue record contains.
Infringement implication: If a competing candidate is a compound covered by the patent’s defined chemical matter, Claim 1 can be asserted based on in vitro and in vivo inhibition activity against hematopoietic cancer cells. The claim’s “contacting” language lowers procedural burden versus pure in vivo administration claims.
Dependent narrowing: Claims 2 and 3 (hematopoietic subtype; enantiomer)
- Claim 2 limits to lymphoma/leukemia/multiple myeloma.
- Claim 3 adds enantiomer specificity: the compound must be the S-enantiomer (or its salt).
Scope consequence: Even if Claim 1 is broad as to compound identity, Claims 2 and 3 narrow the disease biology and strictly require the stereochemical form in that dependent pathway. For challengers, stereochemistry is the key design-around parameter: an R-enantiomer-only compound, an achiral racemate without S-specificity arguments, or a mixture where the asserted compound is not “the S-enantiomer” can affect whether dependent claims are met.
Independent therapeutic use: Claim 4 (explicit compound identity)
Claim 4 is a clean, chemically specific method-of-treatment claim:
- Requires treatment of lymphoma, leukemia or multiple myeloma in a subject.
- Requires administration of an effective amount of a specific chemical entity:
5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one
(or pharmaceutically acceptable salt).
- The claim language does not limit dose regimen or route.
Scope consequence: Claim 4 has high enforceability because it specifies the compound by structure (as text), not just class or genus. It also avoids the “compound definition from spec” ambiguity present in Claim 1.
Dependent disease list: Claim 5
- Claim 5 expands the treated conditions to a defined list including Hodgkin’s and non-Hodgkin’s lymphomas and leukemia/multiple myeloma variants, including chronic myeloid leukemia.
Scope consequence: Since Claim 4 already covers “lymphoma, leukemia or multiple myeloma,” Claim 5 mostly acts as disease-list reinforcement for those exact labels. Practically, it can reduce argument space about whether a particular indication qualifies.
Dependent stereochemical lock: Claim 6
- Claim 6 requires that the compound in Claim 4 is specifically the S-enantiomer (or salt).
Scope consequence: If a product is the S-enantiomer, Claim 6 is directly reachable. If a product is a racemate or R-enantiomer, claim coverage depends on how “the S-enantiomer” is interpreted for the delivered drug substance.
What does the claim language mean for enforcement?
Core claim elements
- Cancer type: “hematopoietic origin” in Claim 1; explicit lymphoma/leukemia/myeloma framing in Claims 2-6.
- Method form:
- Claim 1: contacting cancer cells with effective amount (supports in vitro activity theories).
- Claims 4-6: administering effective amount to a subject (supports clinical and DTC label theories).
- Compound identity:
- Claim 4 defines the molecule by name/structure.
- Claims 3 and 6 require S-enantiomer.
- Effective amount: no dose regimen limitation stated.
Likely infringement pathways
- Product with the named compound: If a marketed drug’s API matches the named structure, Claim 4 and Claim 5 exposure increases.
- S-enantiomer drug: If marketed drug is an S-enantiomer or salt, Claim 3/6 exposure increases, and design-around via stereochemistry becomes central.
- Off-label hematologic use: Method-of-treatment claims can be implicated by physician-directed treatment even when label language differs, depending on evidence of prescribing and administration.
Claim construction pressure points (where disputes typically concentrate)
Even without prosecution history, the written claim set creates repeatable hotspots:
1) “Hematopoietic origin”
Claim 1’s target limitation may be litigated based on whether a cancer is “hematopoietic” versus solid tumor lineages. Claims 4-6 reduce this dispute by anchoring to recognized hematologic disease terms (lymphoma/leukemia/myeloma).
2) “Effective amount”
This is a conventional functional element. For infringement, evidence often centers on:
- pharmacokinetic and dosing data,
- clinical outcome or biomarker effects,
- in vitro potency translated to effective dosing.
3) Enantiomer scope: “S-enantiomer”
Dependent claims 3 and 6 create an explicit stereochemical gate. Typical disputes focus on:
- whether the administered drug is “the S-enantiomer” versus racemate,
- whether a salt form changes the stereochemical analysis (it usually does not change core stereochemistry, but it changes physical form),
- whether a product contains S in a way that meets “is” versus “contains.”
4) Exact chemical definition in Claim 4
The textual chemical name should map to the same scaffold described in the spec. If a competing compound has substitutions or missing functionality, Claim 4 may fall away while Claim 1 could still be argued if Claim 1’s “compound” is broad by genus in the specification.
What is the patent landscape shape around RE44599?
How to position RE44599 in competitive R&D planning
RE44599 sits at the intersection of:
- hematopoietic oncology methods (lymphoma/leukemia/myeloma),
- a specific quinazolinone-like scaffold (as reflected in the named structure),
- stereochemical dependence (S-enantiomer).
This creates a landscape where:
- competitors with the same stereochemically defined API face the highest US risk,
- competitors with related enantiomeric forms or modified scaffolds may reduce exposure if they avoid meeting the dependent S-enantiomer limitations and the explicit Claim 4 structure definition.
Practical landscape mapping (risk ladder)
| Competitive scenario |
Claim exposure profile |
Key gating feature |
| Same structure, S-enantiomer (or salt) used for lymphoma/leukemia/myeloma |
Highest exposure to Claims 4-6 (and likely Claim 1-3 if compound definition matches) |
Named compound identity + S-enantiomer + hematologic indication |
| Same structure, but non-S (R-only or non-stereopure) |
Lower odds for Claim 6/3; potential exposure still exists via Claims 4/1 depending on how “compound” is defined and what stereochemical requirement applies |
Whether “the S-enantiomer” is strictly required to meet dependent claims |
| Similar scaffold (near-structure) |
Depends on whether it falls within the specification-defined “compound” for Claim 1 and whether it matches Claim 4 text identity |
Chemical identity mapping |
| Same general mechanism but different chemical entity |
Primarily avoids Claim 4; may still be tested against Claim 1 if “compound” is broad by genus |
Claim 1 compound definition in the spec (not provided here) |
Business impact: what the claims mean for R&D and freedom-to-operate (FTO)
In-licensing or co-development decisions
- If your candidate is a S-enantiomer of the named molecule, RE44599 claim coverage is directly aligned with intended hematologic indications in Claims 4-6.
- If your candidate is a racemate or non-S stereoisomer, RE44599 still can be a risk, but dependent claims 3/6 are a sharper boundary for design-around arguments.
Product development and label strategy
Because Claim 5 includes explicit subsets of lymphoma/leukemia diagnoses, marketing strategy that avoids those disease terms does not necessarily eliminate method-of-treatment theories when clinicians treat within the disease boundary described by the claim.
Clinical trial strategy
Method-of-treatment claims can be implicated by enrollment protocols that treat:
- lymphoma/leukemia/myeloma broadly, or
- the listed subtypes in Claim 5.
Key Takeaways
- RE44599 is centered on hematopoietic cancer methods (cell growth inhibition and subject treatment) using a specific compound identity in Claim 4.
- Claims 3 and 6 introduce a stereochemical lock requiring the S-enantiomer, creating the primary design-around lever.
- Claim 5 lists multiple hematologic indications, tightening enforcement risk for lymphoma/leukemia/multiple myeloma development programs.
- The highest enforcement exposure occurs when a product uses the named compound and is formulated as the S-enantiomer (or salt) for the covered hematologic disease set.
FAQs
-
Is RE44599 limited to in vitro assays or clinical administration?
It covers both: Claim 1 uses “contacting” cancer cells (in vitro or ex vivo) and Claims 4-6 require “administering” to a subject.
-
Which claim most directly identifies the drug substance?
Claim 4, which specifies 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (or salt).
-
What is the most important design-around feature?
Stereochemistry. Dependent Claims 3 and 6 require the S-enantiomer.
-
Does the patent cover multiple hematologic malignancy subtypes?
Yes. Claim 5 enumerates multiple lymphoma/leukemia categories, including Burkitt’s, Hodgkin’s, non-Hodgkin’s, lymphocytic leukemia, multiple myeloma, and chronic myeloid leukemia.
-
Can development for lymphoma still infringe if the formulation matches but the indication differs slightly?
Claims 4 and 5 use broad disease groupings and a defined list. If the condition fits the claim language (lymphoma/leukemia/myeloma and the listed subsets), indication wording changes may not avoid method coverage.
[1] US Patent RE44599 claim text provided by user (claims 1-6).
